Analysis

Pharmaceutical packaging: where should drug companies focus their efforts?

Pharmaceutical packaging: where should drug companies focus their efforts?

Alzheimer’s drugs: will 2017 bring better news?

Alzheimer’s drugs: will 2017 bring better news?

Takeda turns its focus overseas

Takeda turns its focus overseas

BenevolentAI: using artificial intelligence to speed up drug discovery

BenevolentAI: using artificial intelligence to speed up drug discovery

Takeda and Ovid to Co-develop Drug for Rare Pediatric Epilepsies

Takeda and Ovid to Co-develop Drug for Rare Pediatric Epilepsies

How does the NHS weigh the costs of HIV preventing drugs?

How does the NHS weigh the costs of HIV preventing drugs?

India's drug price overhaul: a question of balance

India's drug price overhaul: a question of balance

Pay-for-delay: how far will companies go to protect market exclusivity?

Pay-for-delay: how far will companies go to protect market exclusivity?

Genomic array could unlock war against diseases in Africa

Genomic array could unlock war against diseases in Africa

Ibuprofen: could this ubiquitous drug be entering a whole new era?

Ibuprofen: could this ubiquitous drug be entering a whole new era?

Pfizer’s big antibiotic buyout: a sign of things to come?

Pfizer’s big antibiotic buyout: a sign of things to come?

Bernie vs. Big Pharma

Bernie vs. Big Pharma

October's top stories: GSK shingles vaccine, Pfizer’s Inflectra injection in US

October's top stories: GSK shingles vaccine, Pfizer’s Inflectra injection in US

Bringing together Oxford and Cambridge’s biopharma clusters

Bringing together Oxford and Cambridge’s biopharma clusters

September's top stories: US researchers developed Epilepsy drugs, GE's €150 million biopharmaceutical campus investment

September's top stories: US researchers developed Epilepsy drugs, GE's €150 million biopharmaceutical campus investment

Pharma Technology Focus – Issue 51

Pharma Technology Focus – Issue 51

Going global: India’s big biosimilar move

Going global: India’s big biosimilar move

Is the stage set for global drug price regulation?

Is the stage set for global drug price regulation?

August's top stories: Pfizer-AstraZeneca $1.5bn deal, Cinven buys Bioclinica for $1.4bn

August's top stories: Pfizer-AstraZeneca $1.5bn deal, Cinven buys Bioclinica for $1.4bn

At long last, a good year for Australia’s pharma industry

At long last, a good year for Australia’s pharma industry

Pharma Technology Focus – Issue 50

Pharma Technology Focus – Issue 50